• The new drug design to involve AI technology for optimization of advanced compounds and boosting up the identification if drug candidates for Almirall drug discovery program.
• The agreement is likely to provide rapid identification of molecules for the satisfaction of multiple bioactivity for clinical trials.
• Under the pact, Almirall would leverage Iktos’s AI accuracy to bring about a difference in the patients’ lives.

One of the prominent AI companies dealing in novel drug design, Iktos, has reportedly announced establishing a research partnership with leading skin-health focused pharmaceutical company, Almirall on the grounds of designing novel drug compounds via the use of Iktos’ AI technology.

As per reliable reports, Iktos’ AI technology offers high speed and efficiency to the drug discovery process through automatically designing virtual molecules that display desirable characteristics of an advanced drug candidate. This is apprehended to tacked one of the fundamental challenges in drug design which is the rapid and repetitive identification of molecules that authenticate the multiple bioactive attributes for testing.

On this acquisition, the executive Vice president R&D and Chief Scientific Officer of Almirall, Dr. Bhushan Hardas was quoted stating that the collaboration serves as an example of how the company intends to explore myriad possibilities served by the technology to discover new molecules and boost the clinical development. He further added that the company has planned to stand at the forefront of innovations to build holistic and transversal approaches in the medical field. AI is anticipated to offer Almirall a distinctive opportunity to amalgamate its skills with an intent to augmenting patients’ lives.

Meanwhile, the president and CEO of Iktos, Yann Gaston- Mathe, cited that the company is delighted to be partnered with Almirall as this collaboration would bolster the leadership position of the company in the domain of AI for new drug design. 

Iktos has of late announced umpteen collaborations and mergers with the biopharmaceutical companies where the company lays immense focus on accelerating the design of promising compounds.

Source credit: https://finance.yahoo.com/news/iktos-almirall-announce-research-collaboration-080100761.html